Engineers Gate Manager LP Voyager Therapeutics, Inc. Transaction History

Engineers Gate Manager LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$7.55 - $11.25 $85,843 - $127,912	-11,370 Reduced 49.8%	11,460 $88,000
Q2 2023 Aug 14, 2023	BUY	$6.94 - $13.99 $158,440 - $319,391	22,830 New	22,830 $261,000
Q2 2022 Aug 15, 2022	BUY	$4.82 - $10.09 $56,572 - $118,426	11,737 New	11,737 $69,000
Q2 2021 Aug 16, 2021	SELL	$3.94 - $5.44 $144,204 - $199,104	-36,600 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$4.61 - $9.04 $168,726 - $330,863	36,600 New	36,600 $172,000
Q3 2020 Nov 16, 2020	SELL	$10.01 - $13.75 $185,515 - $254,828	-18,533 Closed	0 $0
Q2 2020 Aug 17, 2020	SELL	$8.05 - $14.21 $86,867 - $153,340	-10,791 Reduced 36.8%	18,533 $234,000
Q1 2020 May 15, 2020	BUY	$6.8 - $14.66 $53,325 - $114,963	7,842 Added 36.5%	29,324 $268,000
Q4 2019 Feb 14, 2020	BUY	$12.82 - $16.85 $118,841 - $156,199	9,270 Added 75.91%	21,482 $300,000
Q3 2019 Nov 14, 2019	BUY	$16.31 - $28.29 $199,177 - $345,477	12,212 New	12,212 $210,000

130

34.7M

39.7K

34.6K

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $207M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

Get notified when there are updates to the investment portfolio of Engineers Gate Manager LP, based on Form 13F filings with the SEC.

Stay updated on Engineers Gate Manager LP with notifications on news.